BR112012018135A2 - preparação farmacêutica, e, método para fabricar a preparação farmacêutica - Google Patents

preparação farmacêutica, e, método para fabricar a preparação farmacêutica

Info

Publication number
BR112012018135A2
BR112012018135A2 BR112012018135A BR112012018135A BR112012018135A2 BR 112012018135 A2 BR112012018135 A2 BR 112012018135A2 BR 112012018135 A BR112012018135 A BR 112012018135A BR 112012018135 A BR112012018135 A BR 112012018135A BR 112012018135 A2 BR112012018135 A2 BR 112012018135A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical preparation
manufacturing
dosage form
factor
human
Prior art date
Application number
BR112012018135A
Other languages
English (en)
Inventor
Chi-Yu Yang
Li-Chien Chang
Yi-Juain Lin
Original Assignee
Animal Technology Inst Taiwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Animal Technology Inst Taiwan filed Critical Animal Technology Inst Taiwan
Publication of BR112012018135A2 publication Critical patent/BR112012018135A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

preparação farmacêutica, e, método para fabricar a preparação farmacêutica. uma forma de dosagem de liberação lenta do fator ix humano é divulgada. a dita forma de dosagem compreende quantidade terapeuticamente eficaz do fator ix humano que é encapsulado com polímero ou copolímero biodegradável lipofilico para se obter microesferas na formar de pó. a dita forma de dosagem é capaz de liberar o fator ix humano lentamente e prolongar a sua atividade biológica.
BR112012018135A 2010-01-21 2011-01-21 preparação farmacêutica, e, método para fabricar a preparação farmacêutica BR112012018135A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10151282.0A EP2353588B1 (en) 2010-01-21 2010-01-21 A sustained release preparation of factor IX
PCT/CN2011/000102 WO2011088751A1 (zh) 2010-01-21 2011-01-21 第九凝血因子缓释剂型

Publications (1)

Publication Number Publication Date
BR112012018135A2 true BR112012018135A2 (pt) 2016-05-03

Family

ID=42134542

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018135A BR112012018135A2 (pt) 2010-01-21 2011-01-21 preparação farmacêutica, e, método para fabricar a preparação farmacêutica

Country Status (9)

Country Link
US (1) US20130034611A1 (pt)
EP (1) EP2353588B1 (pt)
JP (1) JP2013517305A (pt)
KR (1) KR20130008011A (pt)
CN (1) CN102724969A (pt)
AU (1) AU2011207043A1 (pt)
BR (1) BR112012018135A2 (pt)
SG (1) SG182642A1 (pt)
WO (1) WO2011088751A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356527B (es) 2010-07-09 2018-06-01 Bioverativ Therapeutics Inc Polipeptidos de factor ix y metodos para usarlos.
US20150252345A1 (en) * 2012-09-25 2015-09-10 Biogen Idec Ma Inc. Methods of Using FIX Polypeptides
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
CN104502799B (zh) * 2014-12-16 2017-06-09 河南理工大学 基于量子通信的矿井高压电网短路故障位置自动识别方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA2164957A1 (en) * 1993-06-14 1994-12-22 Sam J. Milstein Protenoid carriers and methods for preparation and use thereof
FR2809309B1 (fr) * 2000-05-23 2004-06-11 Mainelab Microspheres a liberation prolongee pour administration injectable
DK1532985T3 (en) * 2002-06-25 2016-12-05 Takeda Pharmaceuticals Co PROCEDURE FOR PREPARING A COMPOSITION WITH LONG-TERM RELEASE
KR100722607B1 (ko) * 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
NZ585835A (en) 2007-12-27 2012-07-27 Baxter Int Chemically modified factor IX comprising a hydrophilic polymer attached via a releasable linker
CN101461785B (zh) * 2009-01-08 2012-10-17 上海交通大学 水包油-油包油-油包水制备微球的方法
CN101461786A (zh) * 2009-01-08 2009-06-24 上海交通大学 用水包油－油包固体制备的pla/plga壳－核微球及其制备方法

Also Published As

Publication number Publication date
JP2013517305A (ja) 2013-05-16
SG182642A1 (en) 2012-08-30
EP2353588A1 (en) 2011-08-10
US20130034611A1 (en) 2013-02-07
KR20130008011A (ko) 2013-01-21
EP2353588B1 (en) 2015-04-15
AU2011207043A1 (en) 2012-09-06
WO2011088751A1 (zh) 2011-07-28
CN102724969A (zh) 2012-10-10

Similar Documents

Publication Publication Date Title
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
CR20130259A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
CL2011002248A1 (es) Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
CR20120419A (es) Formulación de anticuerpos y regimenes terapéuticos
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112014001091A2 (pt) comprimido resistente à adulteração que fornece liberação imediata do fármaco
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
IL192773A0 (en) Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol
MX348491B (es) Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco.
AR084620A1 (es) Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson
IL222161A (en) Gamma-hydroxybutyrate immediate release and dosage forms
SV2010003674A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
BR112013002814A2 (pt) uso de composição á base de salvia miltiorrhiza na preparação de drogas para a prevenção secundária de doença cárdiocoronariana
NI201000189A (es) Formulación de medicamento sólido con liberación retardadas.
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
CL2013001564A1 (es) Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica.
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
BR112012028788A2 (pt) fabricação de grânulos sem ativos
ES2408343R1 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
UY35091A (es) Formulaciones de liberacion modificada para oprozomib
BR112012018135A2 (pt) preparação farmacêutica, e, método para fabricar a preparação farmacêutica
BR112013014189A8 (pt) composição farmacêutica, uso de um agente de potencialização e uso de uma composição
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
BR112015022398A8 (pt) comprimido de ondansetrona e preparação farmacêutica embalada
CL2013003176A1 (es) Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]